Alkermes News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.05.18	Biotech Stocks Facing FDA Decision In June (RTTNews)
23.05.18	Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting (PR Newswire)
23.05.18	Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting (PR Newswire)
14.05.18	Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference (PR Newswire)
14.05.18	Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference (PR Newswire)
10.05.18	Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference (PR Newswire)
10.05.18	Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference (PR Newswire)
04.05.18	Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders Research (PR Newswire)
04.05.18	Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders Research (PR Newswire)
03.05.18	Alkermes to Host Webcast and Conference Call to Discuss ALKS 3831 Development Program (PR Newswire)
03.05.18	Alkermes to Host Webcast and Conference Call to Discuss ALKS 3831 Development Program (PR Newswire)
02.05.18	Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank 43rd Annual Health Care Conference (PR Newswire)
02.05.18	Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank 43rd Annual Health Care Conference (PR Newswire)
30.04.18	Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual Meeting (PR Newswire)
30.04.18	Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual Meeting (PR Newswire)
26.04.18	Alkermes plc Q1 adjusted earnings Miss Estimates (RTTNews)
26.04.18	Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for Schizophrenia (PR Newswire)
26.04.18	Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for Schizophrenia (PR Newswire)
26.04.18	Alkermes Plc Reports First Quarter 2018 Financial Results (PR Newswire)
26.04.18	Alkermes Plc Reports First Quarter 2018 Financial Results (PR Newswire)
19.04.18	Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results (PR Newswire)
19.04.18	Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results (PR Newswire)
17.04.18	ALKS Pulls Off Sweet Surprise, APRI Thrashed, BMY Gets FDA Nod (RTTNews)
16.04.18	Alkermes Says U.S. FDA Accepts Review Of NDA For ALKS 5461 - Quick Facts (RTTNews)
16.04.18	Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (PR Newswire)
16.04.18	Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (PR Newswire)
03.04.18	RSLS Deflated, ALKS Depressed, ALNY On Watch (RTTNews)
02.04.18	Alkermes Receives Refusal Letter From FDA On NDA Filing For ALKS 5461 (RTTNews)
02.04.18	Alkermes Receives Refusal to File Letter From FDA for ALKS 5461 (PR Newswire)
02.04.18	Alkermes Receives Refusal to File Letter From FDA for ALKS 5461 (PR Newswire)
05.03.18	Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences (PR Newswire)
05.03.18	Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences (PR Newswire)
01.03.18	Alkermes Appoints James Robinson As President And COO - Quick Facts (RTTNews)
01.03.18	Alkermes Appoints James Robinson as President and Chief Operating Officer (PR Newswire)
01.03.18	Alkermes Appoints James Robinson as President and Chief Operating Officer (PR Newswire)
23.02.18	ADXS Falls On Stock Offering, OMER Down 36% In 5 Days, Analyst Downgrades ALKS (RTTNews)
14.02.18	Alkermes Appoints Shane Cooke to Board of Directors (PR Newswire)
14.02.18	Alkermes Appoints Shane Cooke to Board of Directors (PR Newswire)
14.02.18	Alkermes plc Bottom Line Rises In Q4 (RTTNews)
14.02.18	Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2017 and Provides Financial Expectations for 2018 (PR Newswire)
14.02.18	Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2017 and Provides Financial Expectations for 2018 (PR Newswire)
07.02.18	Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results (PR Newswire)
07.02.18	Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results (PR Newswire)
31.01.18	Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder (PR Newswire)
31.01.18	Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder (PR Newswire)
16.12.17	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc of Class Action Lawsuit and Upcoming Deadline - ALKS (PR Newswire)
12.12.17	Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of Securities Class Action Against Alkermes plc (ALKS) (PR Newswire)
02.12.17	ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes plc To Contact The Firm (PR Newswire)
28.11.17	BIIB & ALKS Team Up For MS Drug, REGN's Eylea Combo Fails Again, AEZS Rises (RTTNews)
27.11.17	SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline - January 22, 2018 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Alkermes PLC

Aktien Top/Flop

Meistgelesene Nachrichten